Drug Profile
Research programme: leukaemia therapeutics - Swedish Orphan Biovitrum/Karolinska Development
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Biovitrum
- Developer Biovitrum - Karolinska Development (JV)
- Class Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Leukaemia